Blood test could spot Immunotherapy-Linked liver damage

NCT ID NCT06470997

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to identify specific blood markers that can distinguish hepatitis caused by immune checkpoint inhibitors from other types of autoimmune hepatitis. Researchers will collect blood samples and liver tissue from 60 adults receiving immunotherapy. The goal is to improve diagnosis and treatment of this side effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors quickly identify and treat hepatitis caused by immunotherapy, avoiding unnecessary treatments.

What could go wrong

This is a small, early-stage study focused on finding markers, not testing a treatment. The markers may not prove reliable in larger, more diverse groups.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE-MEDIATED HEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hepatitis primary biliary cholangitis primary sclerosing cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de Montpellier

    RECRUITING

    Montpellier, France, 34295, France

    Contact